title: Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.
abstract: BACKGROUND
  Salivary duct carcinoma (SDC) is an aggressive tumor of the head and neck with a poor prognosis. The objective was to study SDC and recommend the use of trastuzumab as adjuvant therapy.
  
  
  METHODS
  A retrospective chart review of patients seen between 1993 and 2006 was performed. Tumor specimens were examined for HER-2 protein overexpression via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) methods.
  
  
  RESULTS
  Of the 7 patients with SDC, 57% had tumors arising in the parotid gland, the majority having facial nerve paralysis, 71% with nodal disease, and 43% having recurrence. All samples were HER-2 positive on IHC. Three patients had FISH-positive tumors, recurrent disease, and received trastuzumab therapy; 1 of the 3 died after 20 months and a second has shown disappearance of metastatic disease.
  
  
  CONCLUSIONS
  Trastuzumab is effective in treating HER-2-positive breast cancer. Given immunohistochemical similarities between SDC and ductal carcinoma of the breast, patients with FISH-positive HER-2/neu SDC should be considered for trastuzumab therapy.
authors.affiliation: Division of Head and Neck Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, 10833 LeConte Avenue, Los Angeles, California 90095, USA.
authors.forename: Vishad
authors.initials: V
authors.lastname: Nabili
authors.forename: Jesse W
authors.initials: JW
authors.lastname: Tan
authors.forename: Sunita
authors.initials: S
authors.lastname: Bhuta
authors.forename: Joel A
authors.initials: JA
authors.lastname: Sercarz
authors.forename: Christian S
authors.initials: CS
authors.lastname: Head
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D044584:Carcinoma, Ductal / Q000378:metabolism / Q000401:mortality / Q000628:therapy; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000378:metabolism / Q000401:mortality / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D005158:Facial Paralysis / Q000209:etiology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D012189:Retrospective Studies; D012468:Salivary Gland Neoplasms / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D016190:Carboplatin; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human